Biogenesis of p53 involves cotranslational dimerization of monomers and posttranslational dimerization of dimers. Implications on the dominant negative effect.
about
Mechanistic differences in the transcriptional activation of p53 by 14-3-3 isoformsStructural evolution of C-terminal domains in the p53 familySubstrate Shuttling between Active Sites of Uroporphyrinogen Decarboxylase Is Not Required to Generate CoproporphyrinogenMechanism of TAp73 inhibition by ΔNp63 and structural basis of p63/p73 hetero-tetramerizationCo- and Post-Translational Protein Folding in the ERPolyribosomes are molecular 3D nanoprinters that orchestrate the assembly of vault particles.The pharmacodynamics of the p53-Mdm2 targeting drug Nutlin: the role of gene-switching noiseInfluence of Matrices on 3D-Cultured Prostate Cancer Cells' Drug Response and Expression of Drug-Action Associated ProteinsStructure of full-length p53 tumor suppressor probed by chemical cross-linking and mass spectrometry.Antagonistic pleiotropy and p53.Two p53 tetramers bind one consensus DNA response elementChildhood adrenocortical tumours: a review.SCH529074, a small molecule activator of mutant p53, which binds p53 DNA binding domain (DBD), restores growth-suppressive function to mutant p53 and interrupts HDM2-mediated ubiquitination of wild type p53Pathological unfoldomics of uncontrolled chaos: intrinsically disordered proteins and human diseasesLimited importance of the dominant-negative effect of TP53 missense mutationsMutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes.Complementation of two mutant p53: implications for loss of heterozygosity in cancer.The C-terminus of p63 contains multiple regulatory elements with different functions.Only missense mutations affecting the DNA binding domain of p53 influence outcomes in patients with breast carcinoma.Dominant-negative features of mutant TP53 in germline carriers have limited impact on cancer outcomes.Constant rate of p53 tetramerization in response to DNA damage controls the p53 response.Propagation of aggregated p53: Cross-reaction and coaggregation vs. seeding.Stochastic modeling and simulation of the p53-MDM2/MDMX loopCotranslational protein-RNA associations predict protein-protein interactions.p53 and p73 display common and distinct requirements for sequence specific binding to DNAWhole-genome cartography of p53 response elements ranked on transactivation potential.Post-translational modification of p53 in tumorigenesis.Regulation of p53 oligomerization by Ras superfamily protein RBEL1AMutant p53 aggregates into prion-like amyloid oligomers and fibrils: implications for cancer.Low-level p53 expression changes transactivation rules and reveals superactivating sequences.Quality control in oocytes by p63 is based on a spring-loaded activation mechanism on the molecular and cellular level.How many mutant p53 molecules are needed to inactivate a tetramer?Ultraslow oligomerization equilibria of p53 and its implications.Putative RNA-Directed Adaptive Mutations in Cancer Evolution.The role of dimerisation and nuclear transport in the Hes1 gene regulatory network.The tumor suppressor p53: from structures to drug discovery.TP53 mutants in the tower of babel of cancer progression.Widespread cotranslational formation of protein complexes.p53 oligomerization status modulates cell fate decisions between growth, arrest and apoptosis.Quaternary structure of the specific p53-DNA complex reveals the mechanism of p53 mutant dominance
P2860
Q24319736-F08D64E2-BEA9-434A-A36E-A48350353766Q27646113-92059D8B-6F8D-4FE7-913E-44771A82E76BQ27654683-24A5F18B-B315-47C4-B9AA-9D8A3BBD2764Q27728187-753DEE66-AF12-407D-8EF9-55825EDC82BEQ28078736-F0064614-0242-4640-A150-9EC43CBB8DF5Q28250573-568DD37E-5C54-4476-A37B-67A67EFB1CDDQ28542661-974DF124-4DDA-4C67-B0B5-F7C77961634AQ28552225-575AAE7D-8BE9-407A-A897-ED409B68B752Q30316740-B2140673-235C-4D40-B222-6C81B58024B7Q30437532-91C9C79C-A54A-41B8-9BAC-1C58526955C4Q30837439-78A1B2C3-004E-44B9-B3D5-E5D614F26356Q33722503-BA3C5B4A-4142-490B-B0BA-A3FFD6251BC8Q33795918-EBD13B91-C24D-40FB-8558-A25EC187B2D6Q33909288-9B30D648-171F-4DC4-B014-0134C738764AQ33931015-8882EA6D-B7FA-4486-94B0-2C0B0EE6D554Q34292432-FA408402-723D-4CD0-A6FA-9DB577915B98Q34409021-53C4C991-51ED-4297-A0A0-E6E0DBDEBBACQ34546321-5E2B5A2F-5924-4B5D-8CE2-63E4E7712065Q34566248-334CC0EA-EBB5-4E16-8BB1-4296995FEE3DQ34802295-8645B9A8-6B64-46BC-B286-0EB8D22FE4F7Q34986145-FCFB76E9-10EC-48BF-9940-F9F40D78F805Q35134517-D03FD24B-A0E8-4683-9CF6-7F6EBCDC61A2Q35140857-EB33E1E9-95C3-4D36-B0BD-016777550D2CQ35154649-991B4F6B-B75C-4047-996D-64F33E52B063Q35646680-A6BBD1DC-2E42-454D-9FB6-60609D992658Q35665438-01A76AA7-5D82-48FD-816A-8EE4315E3435Q35930703-1CCCF2A4-015B-4161-B93A-AEC5CE18A671Q36075403-8DC59FC4-57EB-4BC6-8352-ABB85B4F40BBQ36201740-F1C704E4-F37D-4502-A05C-FDD5D82A00E4Q36221831-1E668E4C-1E8E-4277-B606-102CCD2C9A3AQ36925989-3862699B-83B9-4F09-A857-B2D7B18B8B68Q37278142-368C4854-969B-4DFB-ACB3-81B68FDAFA49Q37318326-F681C8BC-6510-4A0D-A595-E004B3C3BDEBQ37343623-79B406AC-98FA-4F70-B186-9DE74AF340C0Q37723657-083C5310-179E-424B-BA05-8983164417BFQ37762069-58800E42-B1FB-4545-A685-B73FAD98F076Q38180665-4212BE83-5DC6-4A09-921C-841A5872D135Q38329707-B40246CA-05BB-42D0-8957-3DD68E977CEAQ38740246-8A069E4C-0F27-40FB-A4D3-BEB887AB6B50Q38855681-5980EFB7-AEA5-4DF3-9F8C-030AD3CC4A9E
P2860
Biogenesis of p53 involves cotranslational dimerization of monomers and posttranslational dimerization of dimers. Implications on the dominant negative effect.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
Biogenesis of p53 involves cot ...... the dominant negative effect.
@en
type
label
Biogenesis of p53 involves cot ...... the dominant negative effect.
@en
prefLabel
Biogenesis of p53 involves cot ...... the dominant negative effect.
@en
P2093
P2860
P356
P1476
Biogenesis of p53 involves cot ...... the dominant negative effect.
@en
P2093
Chris D Nicholls
Kevin G McLure
Michael A Shields
Patrick W K Lee
P2860
P304
12937-12945
P356
10.1074/JBC.M108815200
P407
P577
2002-01-22T00:00:00Z